Long-coronavirus disease among people living with HIV in western India: An observational study.
HIV
India
long-COVID
prevalence
risk factors
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
18
05
2021
received:
22
03
2021
accepted:
19
05
2021
pubmed:
3
6
2021
medline:
29
9
2021
entrez:
2
6
2021
Statut:
ppublish
Résumé
Long-COVID is emerging as a significant problem among individuals who recovered from COVID-19. Scant information is available on the prevalence, characteristics, and risk factors for long-COVID among people living with HIV (PLHIV). A tertiary level, private, HIV clinic in western India. A prospective, observational study was conducted to assess the prevalence of long-COVID among PLHIV. Long-COVID was defined as the presence of at least one symptom after 30 days of illness onset. A questionnaire for assessing general, cardiorespiratory, neuro-psychiatric, and gastro-intestinal symptoms was used to screen individuals with history of confirmed COVID-19. Data on demographics, HIV-related variables, comorbidities, and severity of COVID-19 were abstracted from electronic medical records. Univariate and multivariate logistic regression were used to identify risk factors for long-COVID. Ninety-four PLHIV were screened for long-COVID. Median (interquartile range [IQR]) age was 51 (47-56) years and 73.4% were males. The majority (76.6%) had a history of asymptomatic-mild COVID-19 illness. The prevalence of long-COVID was 43.6% (95% confidence interval [CI], 33.4-54.2). Moderate-severe COVID-19 illness was significantly associated with long-COVID (adjusted odds ratio, 4.7; 95% CI, 1.4-17.9; p = .016). Among individuals with long-COVID, cough (22.3%) and fatigue (19.1%) were the commonest symptoms. The median (IQR) duration for resolution of symptoms was 15 (7-30) days. Ten individuals (10.6%) had persistent symptoms at a median of 109 days since the onset of COVID-19. Long-COVID is common among PLHIV with moderate-severe acute COVID-19 illness. There is a need for integration of long-COVID diagnosis and care services within antiretroviral therapy clinics for PLHIV with COVID-19.
Sections du résumé
BACKGROUND
Long-COVID is emerging as a significant problem among individuals who recovered from COVID-19. Scant information is available on the prevalence, characteristics, and risk factors for long-COVID among people living with HIV (PLHIV).
SETTING
A tertiary level, private, HIV clinic in western India.
METHODS
A prospective, observational study was conducted to assess the prevalence of long-COVID among PLHIV. Long-COVID was defined as the presence of at least one symptom after 30 days of illness onset. A questionnaire for assessing general, cardiorespiratory, neuro-psychiatric, and gastro-intestinal symptoms was used to screen individuals with history of confirmed COVID-19. Data on demographics, HIV-related variables, comorbidities, and severity of COVID-19 were abstracted from electronic medical records. Univariate and multivariate logistic regression were used to identify risk factors for long-COVID.
RESULTS
Ninety-four PLHIV were screened for long-COVID. Median (interquartile range [IQR]) age was 51 (47-56) years and 73.4% were males. The majority (76.6%) had a history of asymptomatic-mild COVID-19 illness. The prevalence of long-COVID was 43.6% (95% confidence interval [CI], 33.4-54.2). Moderate-severe COVID-19 illness was significantly associated with long-COVID (adjusted odds ratio, 4.7; 95% CI, 1.4-17.9; p = .016). Among individuals with long-COVID, cough (22.3%) and fatigue (19.1%) were the commonest symptoms. The median (IQR) duration for resolution of symptoms was 15 (7-30) days. Ten individuals (10.6%) had persistent symptoms at a median of 109 days since the onset of COVID-19.
CONCLUSION
Long-COVID is common among PLHIV with moderate-severe acute COVID-19 illness. There is a need for integration of long-COVID diagnosis and care services within antiretroviral therapy clinics for PLHIV with COVID-19.
Identifiants
pubmed: 34078004
doi: 10.1002/iid3.467
pmc: PMC8239760
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1037-1043Informations de copyright
© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Intensive Care Med. 2020 Feb;46(2):329-342
pubmed: 32016535
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
CNS Drugs. 2014 Feb;28(2):131-45
pubmed: 24362768
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Clin Microbiol Infect. 2021 Jan;27(1):89-95
pubmed: 32979574
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Crit Care. 2016 Oct 10;20(1):322
pubmed: 27719675
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
Nat Methods. 2021 May;18(5):449-453
pubmed: 33911230
Immunol Rev. 2013 Jul;254(1):326-42
pubmed: 23772629
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
Ann Intern Med. 2020 Sep 1;173(5):325-330
pubmed: 32628532
PLoS One. 2017 Oct 24;12(10):e0186968
pubmed: 29065165
Immun Inflamm Dis. 2021 Sep;9(3):1037-1043
pubmed: 34078004
Lancet Infect Dis. 2013 Nov;13(11):976-86
pubmed: 24156898
Ann Intern Med. 2021 Apr;174(4):576-578
pubmed: 33175566
Ann Rheum Dis. 2016 Apr;76(4):661-665
pubmed: 27590658
J Antimicrob Chemother. 2019 Nov 1;74(11):3291-3294
pubmed: 31369085
JAMA. 2020 Dec 8;324(22):2251-2252
pubmed: 33206133
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540